1. Home
  2. ABAT vs CLLS Comparison

ABAT vs CLLS Comparison

Compare ABAT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Battery Technology Company

ABAT

American Battery Technology Company

HOLD

Current Price

$3.17

Market Cap

366.2M

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

N/A

Current Price

$4.10

Market Cap

384.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ABAT
CLLS
Founded
2011
1999
Country
United States
France
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
366.2M
384.3M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
ABAT
CLLS
Price
$3.17
$4.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$6.00
$8.33
AVG Volume (30 Days)
4.1M
26.0K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
43.14
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$145.40
N/A
Revenue Next Year
N/A
$0.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.20
$1.33
52 Week High
$11.49
$5.48

Technical Indicators

Market Signals
Indicator
ABAT
CLLS
Relative Strength Index (RSI) 48.75 51.04
Support Level $3.17 $3.39
Resistance Level $3.72 $4.54
Average True Range (ATR) 0.24 0.18
MACD -0.01 -0.03
Stochastic Oscillator 18.97 40.46

Price Performance

Historical Comparison
ABAT
CLLS

About ABAT American Battery Technology Company

American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. Additionally, the company advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company's activities focus on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: